After closing the Series A financing round, the company will advance its plans to create a Phase II contract development and manufacturing organization (CDMO). It has already begun construction of its large scale cell culture media (LSCCM) current good manufacturing processes (cGMP) facilities in Haimen, Nantong, China.
Shun Luo, chairman of Thousand Oaks Biopharmaceuticals, told us the agreement was in an aim to, “build up an integrated CMC bio-manufacturing infrastructure to quickly capture the fast growing biopharmaceutical industry in innovative therapeutics and therapy development.”
In a statement, Luo said that enhancements to its chemistry, manufacturing, and controls (CMC) capabilities will include cell line development, process and bioanalytical development, and customized cell culture media development. Together, these capabilities will establish an integrated platform from DNA to clinical material supplies and regulatory filings.
“Our integrated CMC capacity include those capacities for dry powder cell culture media manufacturing, disposable technology and all its related products including disposable bags and devices,” Luo explained.
The financing was led by New Alliance Capital, and included ADDOR Capital, Tenyall & Sumin, Broadhi Capital, OjanRong, Ji Lin Ao Dong, and Bluebay capital.
